Announcements
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
- Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
- Allakos Announces a Restructuring to Focus on Development of AK006
- Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
- Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
- Allakos Appoints Neil Graham to its Board of Directors
- Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
- Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
More ▼
Key statistics
As of last trade, Allakos Inc (37Z:BER) traded at 1.07, 15.30% above the 52 week low of 0.925 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.07 |
---|---|
High | 1.07 |
Low | 1.07 |
Bid | 1.07 |
Offer | 1.11 |
Previous close | 1.06 |
Average volume | 1.24k |
---|---|
Shares outstanding | 88.54m |
Free float | 86.82m |
P/E (TTM) | -- |
Market cap | 103.60m USD |
EPS (TTM) | -2.14 USD |
Data delayed at least 15 minutes, as of May 07 2024 07:11 BST.
More ▼